WO2002074794A3 - Compositions useful in gene therapy - Google Patents

Compositions useful in gene therapy Download PDF

Info

Publication number
WO2002074794A3
WO2002074794A3 PCT/EP2002/001646 EP0201646W WO02074794A3 WO 2002074794 A3 WO2002074794 A3 WO 2002074794A3 EP 0201646 W EP0201646 W EP 0201646W WO 02074794 A3 WO02074794 A3 WO 02074794A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene therapy
compositions useful
compositions
interest
cells
Prior art date
Application number
PCT/EP2002/001646
Other languages
French (fr)
Other versions
WO2002074794A2 (en
Inventor
Karola Rittner
Eric Jacobs
Original Assignee
Transgene Sa
Karola Rittner
Eric Jacobs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Karola Rittner, Eric Jacobs filed Critical Transgene Sa
Priority to EP02716783A priority Critical patent/EP1363675A2/en
Priority to CA002439315A priority patent/CA2439315A1/en
Priority to JP2002573802A priority patent/JP2004534004A/en
Priority to US10/467,513 priority patent/US20040132188A1/en
Publication of WO2002074794A2 publication Critical patent/WO2002074794A2/en
Publication of WO2002074794A3 publication Critical patent/WO2002074794A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of non-complexing peptides for the preparation of compositions useful for improving transfer of substances of interest into cells. Such compositions are specially useful in gene therapy, vaccination, and any therapeutic or prophylactic situation in which a substance of interest, particularly a nucleic acid is administered to cells in vivo.
PCT/EP2002/001646 2001-02-27 2002-02-15 Compositions useful in gene therapy WO2002074794A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02716783A EP1363675A2 (en) 2001-02-27 2002-02-15 Compositions useful in gene therapy
CA002439315A CA2439315A1 (en) 2001-02-27 2002-02-15 Compositions useful in gene therapy
JP2002573802A JP2004534004A (en) 2001-02-27 2002-02-15 Use of uncomplexed peptides to produce compositions for transfecting polynucleotides into cells and compositions useful in gene therapy
US10/467,513 US20040132188A1 (en) 2001-02-27 2002-02-15 Use of non-complexing peptides for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP01440049 2001-02-27
EP01440049.3 2001-02-27
US27798201P 2001-03-23 2001-03-23
US60/277,982 2001-03-23
EP01440133 2001-05-15
EP01440133.5 2001-05-15
US29318701P 2001-05-25 2001-05-25
US60/293,187 2001-05-25

Publications (2)

Publication Number Publication Date
WO2002074794A2 WO2002074794A2 (en) 2002-09-26
WO2002074794A3 true WO2002074794A3 (en) 2003-02-27

Family

ID=27440161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001646 WO2002074794A2 (en) 2001-02-27 2002-02-15 Compositions useful in gene therapy

Country Status (4)

Country Link
EP (1) EP1363675A2 (en)
JP (1) JP2004534004A (en)
CA (1) CA2439315A1 (en)
WO (1) WO2002074794A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795539B1 (en) * 2005-12-06 2010-12-01 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007069090A2 (en) * 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
CA2805403A1 (en) * 2009-07-10 2011-01-13 Trustees Of Tufts College Bioengineered silk protein-based nucleic acid delivery systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040958A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
EP1161957A1 (en) * 2000-05-26 2001-12-12 Transgene S.A. Complex for transferring an anionic substance of interest into a cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040958A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
EP1161957A1 (en) * 2000-05-26 2001-12-12 Transgene S.A. Complex for transferring an anionic substance of interest into a cell

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADVANCED DRUG DELIVERY REVIEWS, vol. 38, no. 3, 20 August 1999 (1999-08-20), pages 279 - 289, ISSN: 0169-409X *
DATABASE MEDLINE [online] 20 August 1999 (1999-08-20), WAGNER ERNST: "Application of membrane-active peptides for nonviral gene delivery.", XP002180094, Database accession no. 10837761 *
GOTTSCHALK S ET AL: "A NOVEL DNA-PEPTIDE COMPLEX FOR EFFICIENT GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 3, no. 5, 1 May 1996 (1996-05-01), pages 448 - 457, XP000577712, ISSN: 0969-7128 *
RITTNER, KAROLA ET AL: "New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo", MOLECULAR THERAPY (2002), 5(2), 104-114, 2002, XP002222752 *
WYMAN ET AL: "DESIGN, SYNTHESIS, AND CHARACTERIZATION OF A CATIONIC PEPTIDE THAT BINDS TO NUCLEIC ACIDS AND PERMEABILIZES BILAYERS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 36, 1997, pages 3008 - 3017, XP002088731, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
JP2004534004A (en) 2004-11-11
WO2002074794A2 (en) 2002-09-26
CA2439315A1 (en) 2002-09-26
EP1363675A2 (en) 2003-11-26

Similar Documents

Publication Publication Date Title
WO2000071096A3 (en) Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
CA2257133A1 (en) Human dnase i hyperactive variants
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1276756A1 (en) Albumin fusion proteins
HK1053985A1 (en) Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
WO2003030821A3 (en) Albumin fusion proteins
WO2001052874A3 (en) Intra-tumoral administration of il-12 encoding nucleic acid molecules
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO1999040771A3 (en) Concurrent flow mixing for preparing compositions comprising gene therapy vectors
ATE285239T1 (en) VACCINES CONTAINING DNA
WO2004087766A3 (en) Peptabody for cancer treatment
AU2002362060A8 (en) Preparation of red blood cells having reduced immunogenicity
WO2002074794A3 (en) Compositions useful in gene therapy
WO2001003728A3 (en) Gene therapy for enhancing and/or inducing angiogenesis
WO2001057069A3 (en) Targeting peptides
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
CA2334520A1 (en) Treatment of immune diseases
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2001051489A3 (en) Methods for lowering uric acid levels
WO2003052095A3 (en) Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
WO2004031354A3 (en) Human sarcoma-associated antigens
EP2272529A3 (en) DNA vaccine combined with an inducer of tumor cell apoptosis
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
WO2001024832A3 (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
WO1997040134A3 (en) Human dnase ii

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002247723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002716783

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2439315

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002573802

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002716783

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10467513

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002716783

Country of ref document: EP